Brief: Vitura Health And Pharmala Biotech Establish A 50:50 Joint Venture, Called Cortexa
02/05/2023 02:08
May 2 (Reuters) - VITURA HEALTH LTD VIT.AX :
* VITURA HEALTH AND PHARMALA BIOTECH ESTABLISHED A 50:50
JOINT
VENTURE, CALLED CORTEXA
Source text for Eikon: ID:nASX2wN55h
Further company coverage: MDMA.CD
(Reporting by Archishma Iyer)
((Archishma.Iyer@thomsonreuters.com;))
Recent news on Pharmala Biotech Holdings
See all newsBrief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders